PubMed Health⌕ Search

PubMed · 15362888

Absolute configuration modulation attenuated total reflection ir spectroscopy: an in situ method for probing chiral recognition in liquid chromatography.

Abstract

A method to selectively probe the different adsorption of enantiomers at chiral solid-liquid interfaces is applied, which combines attenuated total reflection infrared spectroscopy and modulation spectroscopy. The spectral changes on the surface are followed while the absolute configuration of the adsorbate is changed periodically. Demodulated spectra are calculated by performing a subsequent digital phase-sensitive data analysis. The method is sensitive solely to the difference of the interaction of the two enantiomers with the chiral surface, and the small spectral changes are amplified by the phase-sensitive data analysis. Its potential is demonstrated by investigating an already well-studied system in liquid chromatography, namely, the enantiomer separation of N-3,5-dinitrobenzoyl-(R,S)-leucine (DNB-(R,S)-Leu) using tert-butylcarbamoyl quinine (tBuCQN) as the chiral selector immobilized on the surface of porous silica particles. The performed experiments and density functional theory calculations confirm an interaction model that was proposed earlier based on solution NMR and XRD in the solid state. It emerges that the ionic interaction is the strongest one, but the main reason for the potential for enantioseparation of the chiral stationary phase (CSP) is the distinct formation of a hydrogen bond of the (S)-enantiomer with the chiral selector. This H-bond is established between the amide N-H of DNB-(S)-Leu with the carbamate C=O of the CSP. The (R)-enantiomer instead shows no specific hydrogen bonds. Only the unspecific ionic bonding between the protonated quinine part of the tBuCQN and the carboxylate of the DNB-(R)-Leu (holds also for DNB-(S)-Leu) is observed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ronny Wirz, Thomas Bürgi, Wolfgang Lindner, Alfons Baiker. 2004-09-15. Absolute configuration modulation attenuated total reflection ir spectroscopy: an in situ method for probing chiral recognition in liquid chromatography.. https://doi.org/10.1021/ac049428x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗